Erbitux Package insert

(Cetuximab)

  • Infusion (IV)
  • Head and neck cancer
  • Locally or regionally advanced squamous cell
  • In combination with radiation therapy. Head and neck cancer
  • Metastatic or recurrent squamous cell
  • As monotherapy
  • In patients who failed prior platinum-based therapy. Head and neck cancer
Back to: Full Site Navigation

FDA package inserts for Erbitux (Cetuximab)

This is the FDA package insert, supplied by pharmaceutical companies

Downloading FDA Package Insert for Erbitux intravenous (IV) infusion